CEACAM5 and cancer: Blood‐based routine biomarkers such as cancer antigens (e.g., carbohydrate antigen 15‐3 (CA 15‐3) and Carcinoembryonic antigen (CEA)) used in clinical practice currently have limited sensitivity and specificity; therefore, they are not suitable enough for the BC early diagnosis.